--- title: "08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties" type: "News" locale: "en" url: "https://longbridge.com/en/news/281368752.md" description: "A Drugwatch investigation reveals that pharmaceutical companies prioritize profits over patient safety, with $62 billion in legal penalties from 1991 to 2021 against $1.9 trillion in net income. This indicates a $1 penalty for every $31 profit, suggesting legal consequences are merely a cost of doing business. The report highlights that critical safety information often emerges through litigation rather than regulatory oversight, raising concerns about drug approval processes. The opioid crisis is cited as a case study, revealing undisclosed data only made public through legal action. A companion podcast discusses these findings further." datetime: "2026-04-01T12:35:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281368752.md) - [en](https://longbridge.com/en/news/281368752.md) - [zh-HK](https://longbridge.com/zh-HK/news/281368752.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281368752.md) | [繁體中文](https://longbridge.com/zh-HK/news/281368752.md) # 08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties , /PRNewswire/ -- A new investigation from Drugwatch, _"Big Pharma Behind the Scenes: Patients, Profits and Penalties,"_ uncovers how pharmaceutical industry practices can prioritize profits over patient safety and why lawsuits are often the primary way critical information becomes public. Read the full feature: https://www.drugwatch.com/featured/big-pharma-behind-the-scenes/ Written by investigative journalist Terry Turner, the report highlights a striking imbalance between corporate penalties and financial gains. Between 1991 and 2021, pharmaceutical companies paid more than $62 billion in settlements and fines, while 35 of the largest firms generated approximately $1.9 trillion in net income during a comparable period. Based on Drugwatch analysis, this equates to roughly $1 in penalties for every $31 in profit, reinforcing concerns that legal consequences are often absorbed as a cost of doing business rather than serving as a meaningful deterrent. The investigation also reveals that critical safety information frequently emerges through litigation instead of regulatory oversight, limiting what patients and providers know about risks in real time. Data cited in the report indicates that a significant percentage of drugs failed to meet at least one key clinical trial benchmark, raising questions about the rigor of approval and post-market monitoring processes. The report further explores how aggressive marketing strategies can influence prescribing behavior and accelerate widespread drug use before risks are fully understood. Using the opioid crisis as a case study, the investigation highlights how previously undisclosed data — including the distribution of 76 billion opioid pills, according to DEA data revealed in litigation — only became public through legal action, exposing the scale of corporate decision-making behind the epidemic. A companion podcast expands on these findings, offering a narrative-driven look at the legal, medical and public health implications. Listen to the podcast: https://open.spotify.com/episode/3t8yekxsV0v0aISVwpccvl Terry Turner (\[email protected\]) is available for interviews to discuss the reporting process, key findings and broader industry trends. In addition, Whitney Ray Di Bona, Esq., Drugwatch's in-house attorney and consumer safety advocate, is available to provide legal insight into how litigation exposes hidden risks, why lawsuits often function as a form of regulation and what current enforcement efforts mean for consumer protection. Learn more about Whitney Ray Di Bona: https://www.drugwatch.com/contributors/whitney-ray-di-bona/ Whitney Ray Di Bona can be reached at \[email protected\]. For media inquiries or to coordinate interviews, please contact: Michael Santiago Senior Editor & Public Relations Specialist Drugwatch Phone: 407-225-3268 Email: \[email protected\] Drugwatch is a consumer advocacy organization dedicated to providing trusted information about medications, medical devices and product safety. SOURCE Drugwatch.com ### Related Stocks - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md) - [Invesco Pharmaceuticals ETF (PJP.US)](https://longbridge.com/en/quote/PJP.US.md) - [ProShares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/en/quote/BIS.US.md) - [State Street® SPDR® S&P® PhrmctlsETF (XPH.US)](https://longbridge.com/en/quote/XPH.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [VanEck Pharmaceutical ETF (PPH.US)](https://longbridge.com/en/quote/PPH.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [BlackRock, Inc. (IXJ.AU)](https://longbridge.com/en/quote/IXJ.AU.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) ## Related News & Research - [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md) - [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/en/news/281103720.md) - [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md) - [Centre may bar cancelled drug licence holders from seeking fresh approvals](https://longbridge.com/en/news/281649968.md) - [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/en/news/281644038.md)